Abstract：Objective To study the medication in children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan, China, and to provide a reference for rational drug use in clinical practice. Methods A retrospective analysis was performed on the medical data of the children who were diagnosed with SARS-CoV-2 infection from January 26 to March 5, 2020. The children were divided into an asymptomatic group with 41 children and a symptomatic group with 73 children. A subgroup analysis was performed to investigate the effect of different antiviral regimens (monotherapy, double therapy, or triple therapy) and whether interferon α-1b was used in combination with azithromycin on the length of hospital stay and the clearance time of SARS-CoV-2 nucleic acid. Results A total of 114 children with SARS-CoV-2 infection (72 boys and 42 girls) were enrolled. The median age of the children was 7.1 years. The median length of hospital stay was 10 days and the clearance time of SARS-CoV-2 nucleic acid was 6 days. In either group, the subgroup analysis showed no significance differences in the length of hospital stay and the clearance time of SARS-CoV-2 nucleic acid between the subgroups treated with different combinations of antiviral drugs and the subgroups treated with interferon α-1b alone or in combination with azithromycin (P > 0.05). Conclusions It is not recommended to use the routine combinations of antiviral drugs for children with SARS-COV-2 infection or combine with azithromycin for the purpose of antiviral therapy.
DU Zhao-Song,XU Hua,LIU Mao-Chang. A retrospective analysis of medication in children with SARS-CoV-2 infection in Wuhan, China[J]. CJCP, 2021, 23(1): 61-66.
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern[J]. Lancet, 2020, 395(10223):470-473.
[2]
Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19) outbreak in China:summary of a report of 72314 cases from the Chinese center for disease control and prevention[J]. JAMA, 2020, 323(13):1239-1242.
[3]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of Remdesivir for patients with severe COVID-19[J]. N Engl J Med, 2020, 382(24):2327-2336.
[4]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an openlabel non-randomized clinical trial[J]. Int J Antimicrob Agents, 2020, 56(1):105949.
[5]
Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection[J]. Med Mal Infect, 2020, 50(4):384.
Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China:a descriptive, cross-sectional, multicenter study[J]. Am J Gastroenterol, 2020, 115(5):766-773.
[8]
Sutton D, Fuchs K, D'alton M, et al. Universal screening for SARS-CoV-2 in women admitted for delivery[J]. N Engl J Med, 2020, 382(22):2163-2164.
Drinevskiǐ VP, Osidak LV, Natsina VK, et al. Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children[J]. Antibiot Khimioter, 1998, 43(9):29-34.
[12]
Loosli CG, Stinson SF, Ryan DP, et al. The destruction of type 2 pneumocytes by airborne influenza PR8-A virus; its effect on surfactant and lecithin content of the pneumonic lesions of mice[J]. Chest, 1975, 67(2 Suppl):7S-14S.
[13]
Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia[J]. Curr Opin Immunol, 2015, 34:59-67.
[14]
Madrid PB, Panchal RG, Warren TK, et al. Evaluation of Ebola virus inhibitors for drug repurposing[J]. ACS Infect Dis, 2015, 1(7):317-326.
[15]
Retallack H, Di Lullo E, Arias C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin[J]. Proc Natl Acad Sci U S A, 2016, 113(50):14408-14413.
